-
Is startup biotech funding at risk?
Mike WokaschOver the past couple of decades, small biotech companies have been an invaluable source of exciting new drug treatments. As a result, investors have been handsomely rewarded for funding these high-risk, speculative technologies that helped fill depleted Big Pharma pipelines. Companies with any hope for delivering a return on investor money have two possibilities; have one of their technologies acquired or have the entire company acquired by a cash rich Big Pharma or Big Biotech.
-
The ultimate proposal editing checklist: 7 steps to a more persuasive document
Joe LattaProposals are important. And with a growing focus on procurement transparency and objectivity, a high quality proposal can mean the difference between a big win and an almost-was.
-
Finding the right partner to solve the lyophilization challenge
Peter SoelknerAbout 30 percent of all parenteral drugs approved by the FDA in the past few years involved freeze-dried substances. Experts are predicting a possible rise to even 50 per cent in the future. It's definitely a challenge for R&D as well as commercial filling. Therefore many pharmaceutical and biotech companies rely on outsourcing partners. But how to find the right partner for the challenge?
-
Getting green and energy independent: Nice try?
Stefanie Heerwig"We'll continue our march towards energy independence and address the threat of climate change," President Barack Obama announced ambitiously April 10, 2013. According to his proposal, the U.S. should half its oil imports by 2020 and double its energy productivity by 2030. A high aim, but possible as some experts like Christine McEntee, executive director and CEO of the American Geophysical Union, suggest, especially because the plan is carefully tailored and radically wide-ranging.
-
Big Pharma replaces innovation with acquisition
Mike WokaschBig Pharma (including Big Biotech) has executed about 130 mergers or acquisitions in each of the past couple of years. The overwhelming majority of deals designed to fill depleted Big Pharma pipelines with more novel and innovative technologies in later stages (closer to market) than their own R&D had been able to produce.
-
918 Spyder: The future of Porsche
David HurthAt the 2013 Frankfurt International Motor Show, the Porsche 918 Spyder stole the show. You may be thinking, didn’t that car debut three years ago? Yes, it did, but this year’s show unveiled the final production version to the public.
-
Specialty processing techniques advancing electronic end-use development
Don RosatoEnd-use electronic application plastic process development is responding to the ongoing need for smaller electronic devices that in turn call for smaller, thinner electrical components. Convergence among computer, consumer electronics and telecom industries continue to blur the lines between information, entertainment and communication.
All Manufacturing Articles